A new study published in the journal of BMC Nephrology showed that in patients receiving hemodialysis, supplementing with n-3 polyunsaturated fatty acids (omega-3 PUFAs) dramatically decreased cardiovascular mortality, myocardial infarction, and vascular access-related events. Hemodialysis patients with end-stage renal illness had disproportionately high rates of thrombosis, chronic systemic inflammation, and cardiovascular death. As a result, this study assessed how n-3 PUFA supplementation affected hemodialysis patients. Overall, in hemodialysis patients, n-3 PUFA supplementation dramatically lowers cardiovascular mortality, myocardial infarction, and vascular access events without changing all-cause mortality. Impact of OMEGA-3 fatty acid in patients undergoing hemodialysis: a systematic review and meta-analysis.